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Cyclic guanosinemonophosphate (cGMP) and cyclic
AMP (cAMP)-dependent protein kinases (PKG and
PKA) are closely related homologs, and the cyclic
nucleotide specificity of each kinase is crucial for
keeping the two signaling pathways segregated,
but the molecular mechanism of cyclic nucleotide
selectivity is unknown. Here, we report that the
PKG Ib C-terminal cyclic nucleotide binding domain
(CNB-B) is highly selective for cGMP binding, and
we have solved crystal structures of CNB-B with
and without bound cGMP. These structures, com-
bined with a comprehensive mutagenic analysis,
allowed us to identify Leu296 and Arg297 as key
residues that mediate cGMP selectivity. In addition,
by comparing the cGMP bound and unbound struc-
tures, we observed large conformational changes in
the C-terminal helices in response to cGMP binding,
which were stabilized by recruitment of Tyr351 as
a ‘‘capping residue’’ for cGMP. The observed rear-
rangements of the C-terminal helices provide a me-
chanical insight into release of the catalytic domain
and kinase activation.
INTRODUCTION
PKG and PKA are homologous kinases in the protein kinase
A, G, and C family that mediate pathway-specific cellular re-
sponses through the phosphorylation of unique substrates and
downstream effectors, often regulating opposing physiological
responses; for example, in cardiac tissue, cyclic AMP (cAMP)
has been shown to cause positive inotropy, while cyclic guano-
sine monophosphate (cGMP) has been shown to cause negative
inotropy (Beavo and Brunton, 2002; Francis and Corbin, 1999;116 Structure 22, 116–124, January 7, 2014 ª2014 Elsevier Ltd All rigPearce et al., 2010; Rehmann et al., 2007; Schlossmann and
Hofmann, 2005). While PKG and PKA signaling specificity is
mediated in part through subcellular compartmentalization
and protein-protein interactions (Francis et al., 2010), specific
binding of each cyclic nucleotide is crucial for keeping the two
signaling pathways segregated at the molecular level. At this
time, the molecular mechanism of cyclic nucleotide selectivity
is poorly understood.
PKG is a central downstream mediator of the nitric oxide-
cGMP signaling pathway and regulates key physiological pro-
cesses such as vasodilation, inhibition of platelet aggregation,
nociception, and smooth muscle tone (Francis et al., 2010).
Genetic ablation of PKG in mice results in phenotypes that
reflect the necessity of the kinase in vivo. For example, PKG I
knockout mice have a hypertensive phenotype, have dysfunc-
tional smooth muscle contraction, and die at an early age due
to loss of intestinal peristalsis (Pfeifer et al., 1998). Furthermore,
a recent study identified amutation in human PKG Ia that causes
thoracic aortic aneurysms and dissections, demonstrating the
importance of proper cGMP/PKG Ia signaling to normal aortic
function (Guo et al., 2013). These observations, combined with
the fact that many existing therapeutics act indirectly on PKG
by elevating cellular cGMP levels, has generated interest in tar-
geting PKG directly with PKG-specific activators (Schlossmann
and Hofmann, 2005). However, this approach is hampered by
the lack of structural information on PKG and an incomplete
mechanistic understanding of how PKG is specifically activated
by cGMP.
PKG I can be divided into N-terminal regulatory (R)- and
C-terminal catalytic (C)-domains. PKG I has two splice variants,
PKG Ia and PKG Ib, which differ in their first 100 amino acids,
giving each isoform unique dimerization and autoinhibitory
domains, conferring differences in cyclic nucleotide binding
(CNB) affinity, and modulating the ability of cGMP to induce
kinase activation (Ruth et al., 1991). These are followed by the
two CNB domains (CNB-A and CNB-B) that bind cGMP with
different affinities and that make up the rest of the regulatory
domain (Francis and Corbin, 1999) (Figure 1A). The CNB domainhts reserved
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Figure 1. Domain Organization and Overall Structure of the PKG Ib (219–369):cGMP Complex
(A) Domain organization of PKG Ib with CNB-B highlighted. AI: autoinhibitor sequence.
(B) Affinity measurements of PKG Ib (219–369) for cGMP and cAMP. The construct has a 240-fold selectivity for cGMP. Competition FP curves are shown in red,
and competition SPR curves are shown in black. Error bars denote SEM.
(C) Overall structure of the PKG Ib 219–369:cGMP complex with the secondary structure elements labeled. The PBC is yellow, the aB and aC helices are red,
the N-terminal helices are teal, and cGMP is colored by atom type, with carbon colored white, nitrogen colored blue, oxygen colored red, and phosphorus
colored orange. The N and C termini are labeled with their corresponding residue number seen in the final model. The disordered b4-b5 loop in the PKG Ib
(219–369):cGMP complex is shown as a dotted line. All structure images were generated using PyMOL (Delano Scientific).
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Mechanism of cGMP-Selective Activation of PKG Iis a regulatorymodule that is highly conserved in diverse proteins
such as PKA, the catabolite activator protein, cyclic nucleotide-
gated (CNG) and hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels, and exchange proteins activated by
cAMP. The domain consists of approximately 120 residues form-
ing an eight-stranded b barrel with a variable number of a helices
(Berman et al., 2005; Rehmann et al., 2007). The CNB site is
located within the b barrel, with the cyclic phosphate making
multiple contacts with residues at the base of the barrel in a
structure referred to as the phosphate binding cassette (PBC),
which consists of a short helix followed by a loop between b
strand 6 and b strand 7. In the absence of cGMP, the R-domain
binds and inhibits the C-domain. Binding of cGMP to both sites
in the R-domain is required for full kinase activation, and cGMP-
induced conformational changes in the R-domain release and
activate the C-domain (Alverdi et al., 2008; Rehmann et al.,
2007; Smith et al., 2000; Wall et al., 2003). However, the under-
lying molecular mechanism that allows cGMP to drive this
conformational change is unknown. Here, we report high
resolution structures of the C-terminal CNB domain, CNB-B, of
PKG I with and without cGMP. These structures reveal the
mechanism for cGMP selectivity in PKG I and allow us to pro-
pose a mechanism for cGMP-selective activation.
RESULTS
PKG I CNB-B Is Responsible for cGMP Selectivity
We previously found that PKG I CNB-A bound both cGMP and
cAMP with relatively high affinity (12 ± 1.6 versus 27 ± 3.6 nM,
respectively). While crystal structures of the N-terminal CNB
(CNB-A) of PKG Ib and tandem CNBs (CNB-A/B) of PKG Ia are
available (Kim et al., 2011; Osborne et al., 2011), only the formerStructure 22, 11was solved with bound cGMP, revealing specific contacts be-
tween residues in the CNB-A b5 strand and cGMP. Despite
these contacts, the fact that CNB-A of PKG Ib shows poor cyclic
nucleotide selectivity indicates that other domains are required
to mediate cGMP specificity (Kim et al., 2011).
Therefore, we decided to test whether the PKG I CNB-B
domain (PKG Ib residues 219–369) bound cGMP selectively.
Using competition fluorescence polarization (FP), we found
that the PKG I CNB-B domain binds cGMP with a half maximal
effective concentration (EC50) of 215 nM, whereas it binds
cAMP with an EC50 of 52 mM (Figure 1B; Table S1 available
online). Thus, affinity for cGMP over cAMP is approximately
240-fold higher in the CNB-B domain, and from this result, we
conclude that CNB-B represents the minimal domain required
for cGMP selectivity in PKG I.
Strand b5 and the aC-Helix Provide Novel Interactions
for cGMP
To understand the structural basis for cGMP selectivity seen in
CNB-B, we solved a crystal structure of CNB-B bound to
cGMP at 1.65A˚ resolution using iodide single wavelength
anomalous dispersion (SAD) for phase determination (Figure 1C
and Table 1). The final model includes residues 223–351 with the
large portion of the C terminus disordered (residues 352–369).
The structure of the CNB-B:cGMP complex clearly shows
electron density for cGMP in the syn configuration at the PBC
(Figure S1). The interactions between CNB-B and the ribose
and the cyclic phosphate of cGMP are virtually identical to those
seen in the CNB-A:cGMP complex (Figure S2) (Kim et al., 2011).
In addition, Thr317 forms hydrogen bonds with guanine that
mirror those seen between cGMP and Thr193. However, other
interactions with the guanine moiety are distinct in CNB-B. The6–124, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 117
Table 1. Data and Refinement Statistics
Statistics Apo
cGMP-Bound
High-Resolution
cGMP-Bound
(Iodine SAD)
Data Collection
Wavelength (A˚) 0.97931 0.97931 1.54178
Space group P3121 P41212 P41212
Cell dimensions
a,b,c (A˚) 78.8,78.8,
147.6
47.2, 47.2,
101.9
47.9,47.9,
104.1
a,b,g () 90,90,120 90,90,90 90,90,90
Resolution (A˚) 36.9–2.00 23.8–1.65 15.0–1.80
Rsym or Rmerge 11.4 (45.1)
a 7.7 (47.1) 6.0 (21.4)
I/sI 10.2 (3.4) 20.1 (5.5) 32.2 (2.1)
Completeness (%) 99.4 (96.4) 99.6 (100) 91.2 (35.7)
Redundancy 4.8 (4.4) 13.5 (13.8) 7.2 (5.9)
Refinement
Resolution (A˚) 36.9–2.00 23.8–1.65 15.0–1.80
No. reflections 36,516 14,492 19,090
Rwork/Rfree
b 18.82/22.69 19.74/24.47 18.9/24.4
No. atoms
Proteins 2,934 985 985
Ligand/ion 14 46 45
Water 343 68 56
B-factors
Protein 46.424 28.464 37.069
Ligand/ion 83.734 32.253 49.169
Water 45.140 38.431 37.139
Rmsd
Bond lengths (A˚) 0.006 0.006 0.007
Bond angles () 0.980 1.093 1.149
aHighest resolution shell is shown in parentheses.
b5.0% of the observed intensities was excluded from refinement for
cross-validation purposes.
Structure
Mechanism of cGMP-Selective Activation of PKG ICNB-B:cGMP complex reveals that Leu296 and Arg297 on the
b5 strand provide a specific docking site for cGMP (Figure 2A).
Leu296 interacts with the guanine through Van der Waals
(VDW) interactions, whereas Arg297 interacts through two
hydrogen bonds. The unique side chain orientation of Arg297
aligns its guanidinium group with the guanine ring, placing its
amine and protonated Nε within hydrogen bonding distance of
the C6 carbonyl and unprotonatedN7 nitrogen of cGMP, respec-
tively (Figure S3). Notably, although they are consecutive resi-
dues, the unusual backbone geometry at this region enables
both side chains of Leu296 and Arg297 to point toward the bind-
ing pocket and interact with cGMP.
In our previous crystal structure of the CNB-A:cGMP complex,
the side chain of Leu172, which is in an position analogous to
that of Leu296, interacts with cGMP in a similar manner (Kim
et al., 2011). However, Cys173, corresponding to Arg297 in
CNB-B, does not form hydrogen bonds and only shows VDW
interaction with the guanine moiety (Figure S2). The absence of
these contacts may, at least partially, explain why CNB-A is
not selective for cGMP. Moreover, in the b5 strand of PKA RIa,
Val313 and Gly314 reside in positions analogous to those of118 Structure 22, 116–124, January 7, 2014 ª2014 Elsevier Ltd All rigLeu296 and Arg297 of PKG Ib and do not interact with cAMP
(Figures 2B and 2C) (Su et al., 1995). Similarly, in the b5 strand
of PKA RIIb, Ile339 and Ala440 reside in positions analogous to
those of Leu296 and Arg297 of PKGIb and form only VDW
interactions with cAMP (Diller et al., 2001). These structural
differences provide evidence that support the role of Arg297 in
mediating cGMP selectivity.
In addition to the interactions at the b5 strand, the CNB-
B:cGMP complex structure shows that Tyr351 in the aC helix
interacts with cGMP through ap stacking interaction (Figure 2A).
This finding is consistent with our previous hydrogen/deuterium
(H/D) exchange data, which showed that cGMP induced the
slowing of H/D exchange around Tyr351 (Lee et al., 2011). The
phenol group of Tyr351 interacts with one side of the guanine
moiety, sandwiching it against Leu296 (Figure 2A). Unlike the
continuous helix seen in PKA RIa, the aC helix shows only one
helical turn followed by a short loop (Figures 2B and 2C)
(Su et al., 1995). Despite low sequence and structural similarity
at this region, superimposing PKA and PKG structures shows
that Tyr351 of PKG Ib overlaps with Tyr371 of RIa and that
these tyrosines act as ‘‘capping residues’’ for the CNB pockets
(Figures 2C and 2D).
Mutagenesis of Contact Residues Results in Reduced
cGMP Selectivity and Activation
To test the contributions of Leu296, Arg297, Thr317, and Tyr351
to cGMP selectivity, we mutated them one at a time to alanine
and measured cGMP and cAMP affinities of the mutants.
Mutating any of these residues dramatically reduces cGMP
affinity with relatively little change in cAMP affinity (Table S1).
Next, we mutated these residues in full-length PKG Ib (residues
5–686) and measured their effect on kinase activation using
a microfluidic mobility-shift assay. Mutating any of these resi-
dues except Thr317 increases activation constants (Ka) for
cGMP (Table S2). Consistent with these observations, a previous
study measuring the contribution of Thr317 to cGMP-dependent
activation reported only a minor increase in Ka on replacing this
residue with an alanine (Reed et al., 1996). In contrast, our data
show that Leu296, Arg297, and Tyr351 in PKG I are important
not only for the cGMP binding but also for kinase activation.
Binding of cGMP Induces Large Conformational
Changes in the CNB-B Helices
To investigate the structural changes upon cGMP binding, we
obtained a crystal structure of CNB-B in the absence of cGMP.
The apo structure was solved by molecular replacement (MR)
at 2.00 A˚ resolution using the CNB-B:cGMP complex as a MR
model. The apo structure contains three molecules per unit cell
(Figure S4). Independent of the different packing environments,
the overall structures of all three molecules in the unit cell are
very similar with root-mean-square deviation (rmsd) values of
less than 1 A˚ for at least 80 Ca atoms. Only one of three mole-
cules in the unit cell showed most of the helical subdomains,
whichwere stabilized by crystal contacts (Figure S4C), indicating
that the helical domains in the isolated CNB-B are highly dy-
namic in the absence of cGMP. The final model for the ordered
molecule contained residues 217–365. Comparing the apo
structure to the cGMP-bound structure shows that the b barrel
regions do not vary, whereas the helical subdomains undergohts reserved
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Figure 2. cGMP Binding Pocket of CNB-B and
Its Comparison with the PKA:cAMP Complex
(A) Detailed interactions between cGMP and CNB-B.
Zoomed-in views for each cGMP binding site are
shown on either side. The individual cGMP interact-
ing residues are shown, with the following color
theme: side chain carbon, black; oxygen, red; nitro-
gen, blue. The cyclic nucleotide, b5, and capping
residues are shown with transparent surface. Con-
tacts are shown as dotted lines with their distances
(A˚).
(B) Comparison between the PKG Ib cGMP binding
pocket and PKARIa cAMPpocket. The cGMPpocket
of PKG Ib in red is shown on the left panel, and the
cAMP binding pocket of PKA RIa (PDB code: 1RGS)
in gray is shown on the right. Key cyclic nucleotide
binding residues are shown as sticks. An ordered
water molecule is shown as a blue sphere.
(C) Superposition of two structures shown in (B) are
shown on the left, with a zoomed-in view on the right
(cyclic nucleotides are shown as white sticks).
(D) Sequence alignments of CNB-B from PKG Ib and
PKA RIa. Conserved residues are shaded in yellow,
and cyclic nucleotide-interacting residues through
their side chains are shaded in red for both proteins.
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Mechanism of cGMP-Selective Activation of PKG Imajor conformational changes (Figure 3; Figure S5). The struc-
tural changes occur in three distinct regions of CNB-B: the
PBC, the aB helix, and the aC helix. In the absence of cGMP,
the PBC is in a open conformation, tilting away from the rest of
the b barrel. The aB helix interacts with the aA helix mainly
through hydrophobic interactions formed between amphipathic
helices running parallel to each other. Upon cGMP binding, the
aBhelix andPBC, coupled throughahydrophobic interaction be-
tween Leu310 and Phe336, tilt toward the b barrel in a concerted
motion (Figure 3A). The closer proximity of the aB helix to the
binding pocket then allows the flexible aC helix to close on to
the binding pocket, resulting in capping of cGMP by Tyr351.
Of all thesemovements, themost drastic change occurs at the
aC helix. For the molecule in the apo structure with ordered he-
lical subdomains, the aC helix is more ordered compared to the
cGMP-bound structure, showing five additional helical turns
(Figure 3A). Tyr351 is on the second turn of the aC helix and
not at the end of a loop, as seen in the cGMP-bound complex.
Due to these structural changes, the capping residues are overStructure 22, 116–124, January 7, 2020 A˚ apart between the bound and unbound
structures (Figure 3B). Gly341 and Gly342
located between the aB and aC helices
seem to form a flexible ‘‘Gly-Gly hinge,’’
enabling the large conformational flexibility
(Figure 3A). This Gly-Gly hinge partly
explains why the overall position of the aB
and aC helices is dramatically different be-
tween the apo and cGMP bound structures.
The Gly-Gly Hinge Allows
Conformational Flexibility of the aB
and aC Helices
Next, we compared our structures with the
crystal structure of PKG Ia CNB-A/B re-ported by Osborne et al. (2011). Excluding dramatic conforma-
tional differences at the aC helix, their structure of PKG Ia
CNB-A/B closely resembles our apo structure, which is unsur-
prising since its CNB-B also lacked cGMP (Figure S6). In their
structure, the aC helix (corresponding to residues 347–371 in
PKG Ib) is completely removed from the rest of CNB-B and forms
an 90 angle compared to our apo CNB-B. Furthermore, the
capping residues are over 18 A˚ apart between the two struc-
tures. Since both PKG I isoforms have the same amino acid
sequence at this region, these differences could be explained
in part by the flexible Gly-Gly hinge, which enables multiple con-
formations of the aC helix that can be stabilized in different con-
formations by alternative crystal packing. Specifically, PKG Ia
CNB-A/B formed a noncrystallographic symmetry-related dimer
through the hydrophobic contacts (referred to as a ‘‘knob-nest’’
assembly) between the aC helix of one protomer and CNB-B of
the other, and these contacts likely stabilized the open confor-
mation of the aC helix. However, although the CNB-B domain
of PKG Ib contains the corresponding residues that form these14 ª2014 Elsevier Ltd All rights reserved 119
AB
Figure 3. Structural Comparison between
the apo- and cGMP-Bound PKG Ib (219–369)
(A) Regions mediating cGMP interactions are
shown. The disordered b4-b5 loop and disordered
portion of the aC helix are indicated with a dotted
line. The Ca atoms of the Gly-Gly hinge residues
(Gly341 and Gly342) are shown as balls. Leu310,
Phe336, Tyr351, and cGMP are shown as sticks
with transparent surface.
(B) The apo (gray) and PKG Ib 219–369:cGMP
(red) structures aligned at the b-barrel region.
An enhanced view of the binding pocket high-
lighting the b5 and capping residue interactions
with cGMP (black sticks) is shown on the right. In
the apo structure, the side chain of Arg297 is
extended in a conformation partially occupying
the empty cGMP binding pocket.
Structure
Mechanism of cGMP-Selective Activation of PKG Icontacts, our apo structure shows no such ‘‘knob-nest’’ assem-
bly, as residues 366–369 corresponding to the knob are disor-
dered (Figure S4).
To investigate the structural changes associated with
cGMP binding in solution, we used nuclear magnetic reso-
nance (NMR) to obtain secondary structure probabilities of
the aB and aC helices. In the presence of cGMP, the secondary
structural probabilities agreed well with the crystal structure,
indicating that crystal packing minimally influences their confor-
mation (Figure S7). Additionally, residues 352–369, which were
disordered in the crystal structure, show a low probability of
being an a helix in solution. In the absence of cGMP, NMR
showed very little a helix preference in these C-terminal resi-
dues. This finding corresponds to the fact that two of the mol-
ecules in the unit cell of the apo structure showed no electron
density for this region, and the one molecule that was struc-
tured was stabilized by crystal contacts, again indicating that
this region is more dynamic in the absence of cGMP. Further-
more, dilution of the sample resulted in no significant change in
1H,15N heteronuclear single quantum coherence (HSQC)
spectra, suggesting no change in oligomerization state
between these two concentrations (Figure S8A). Finally, we
tested whether PKG Ib 92-369, a construct containing CNB-A
and CNB-B that aligns closely with PKG Ia CNB-A/B, migrates
as a dimer on a size exclusion column (Figures S8B and S8C).
The elution profile of PKG Ib 92-369 is consistent with a mono-
meric 48 kDa species, suggesting that the interchain interface
between aC helices described by Osborne et al. (2011) is a
crystal contact unlikely to occur in solution. Taken together,
these results demonstrate that the aB and aC helices of
CNB-B are more flexible without cGMP in solution and support
the observation derived from our crystal structures that the aB
and aC helices close on to the binding pocket on cGMP
binding.120 Structure 22, 116–124, January 7, 2014 ª2014 Elsevier Ltd All rights reservedDISCUSSION
The biochemical and structural data pre-
sented here clearly demonstrate the
high cGMP selectivity of CNB-B in PKG
I and reveal specific amino acid contacts
that explain its high selectivity. In light ofthe finding that CNB-A is not selective for cGMP (Kim et al.,
2011), our measurements demonstrating 240-fold selectivity
for cGMP in CNB-B, combined with our data demonstrating
that mutations that disrupt CNB-B’s interaction with cGMP
significantly decrease the ability of cGMP to activate full-length
PKG I, suggest that CNB-B is not only a minimal construct selec-
tive for cGMP but is also responsible for conferring cGMP selec-
tivity to full-length PKG I. While its overall fold and interaction
with cGMP are similar to those of CNB-A, the structures of
CNB-B reveal unique Leu296 and Arg297 residues on the b5
strand that explain the high selectivity for cGMP. Specifically,
while Cys173 at the analogous position on the b5 strand of
CNB-A makes a weak VDW interaction with cGMP, the side
chain of Arg297 forms two strong hydrogen bonds with the gua-
nine moiety. Additionally, because mutating Arg297 to alanine
partially improves affinity for cAMP, we hypothesized that
Arg297 on the b5 strand acts as a filter for cAMP by weakening
CNB-B’s affinity for cAMP. Consistent with this hypothesis, a
conserved glycine is located at the analogous position in the
PKA RIa subunit. Taken together, these results demonstrate
that the high selectivity of full-length PKG I is achieved in part
by the placement of Arg297 in CNB-B, which forms specific in-
teractions with cGMP while reducing affinity for cAMP.
More generally, our results allow us to propose the role of
CNB-B in mediating cGMP-specific signaling. Studies on intra-
cellular levels of cGMP and cAMP in intact cells reported that,
while they are in constant flux, the highest concentrations
range between 2 and 5 mM for cGMP or cAMP (Ponsioen
et al., 2004; Trivedi and Kramer, 1998). Previous reports in
the literature have observed that, at these concentrations,
crosstalk between the cGMP and cAMP pathways can occur
through the binding of cGMP to PKA or binding of cAMP to
PKG, resulting in at least partial activation of these kinases
and affecting physiological outcome (Cornwell et al., 1994;
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Figure 4. Role of CNB-B in Activation and
Stepwise Model for cGMP Binding
(A) Role of cGMP contact residues in kinase
activation. Ka values were measured using a
microfluidic mobility shift assay, and error bars
denote SEM.
(B) Stepwise model for cGMP binding and kinase
activation. In Step 1, cGMP binds to the pocket,
interacting with the PBC and the b5 strand. In Step
2, this interaction causes the PBC to tilt toward the
core of CNB-B, causing the aB and aC helices to
compact against the binding pocket. Step 3,
shows the capping of cGMP by Tyr351. In Step 4,
the capping interaction stabilizes the activated
conformation of CNB-B, dislodging the C-domain
and activating the enzyme.
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Mechanism of cGMP-Selective Activation of PKG IJiang et al., 1992; Komalavilas and Lincoln, 1996). However,
since these levels of cyclic nucleotide are far below CNB-B’s
EC50 for cAMP (52 mM), but well above its EC50 for cGMP
(215 nM), full activation of PKG I likely occurs only in response
to cGMP. Thus, CNB-B plays a ‘‘checkpoint’’ role by limiting
cAMP-mediated activation of PKG I. Consistent with this hy-
pothesis, biochemical evidence and small-angle X-ray scat-
tering (SAXS) data suggested that binding of cGMP to CNB-B
is required for the full activation of PKG I (Francis and Corbin,
1999; Smith et al., 2000; Wall et al., 2003). Although crosstalk
between the cGMP and cAMP pathways can affect physio-
logical outcome, the observation that cGMP and cAMP can
mediate drastically different physiological responses in specific
environments, such as negative and positive inotropy in cardiac
tissue, suggests a need for CNB-B in PKG to filter out cAMP
and limit crosstalk between these two signaling pathways, at
least in certain tissues (Huang et al., 1999; Pellegrino et al.,
2009). Thus, our data provide key insights for developing
PKG-selective activators in the rational design of antihyperten-
sive therapeutics.
Additionally, our structures show that Tyr351 provides a
capping interaction for cGMP in PKG I. This aromatic residue
at the aChelix undergoes ap stacking interaction with the bound
cyclic nucleotide, and a similar interaction is found in PKA CNB
domains (Su et al., 1995; Wu et al., 2004). Specifically, compar-
ison of our structure of PKG I CNB-B with the structures of PKA
RIa CNB-B domain shows that Tyr351 of PKG Ib structurally
aligns with Tyr371 of RIa. Because it forms a hydrophobic inter-
action with cyclic nucleotides seen also in PKA subunits, we hy-
pothesized that Tyr351 does not contribute to cGMP selectivity
but instead stabilizes the activated conformation through the
capping interaction. Indeed, comparison of the cGMP-bound
and apo structures of CNB-B revealed dramatic conformational
changes in the aC helix, enabled by the flexibility of the Gly-Gly
hinge and by the capping interaction (Figure 4). Furthermore,Structure 22, 116–124, January 7, 2014mutating Tyr351 to alanine reduces bind-
ing affinity and increases Ka values for
both cGMP and cAMP, confirming the
role of Tyr351 in both CNB and kinase
activation. Thus, we hypothesize that
this capping interaction provides an allo-
steric mechanism of activation by drasti-cally changing the conformation of the aC helix upon cGMP
binding.
Our findings describing the dynamic nature of the aC helix,
and its rearrangement on CNB, are consistent with those
of studies on other CNB-containing proteins. As previously
mentioned, structures of the PKA RIa have demonstrated that
conformational changes occur in the aC helix on cAMP binding,
and these changes provide an allostericmechanism of activation
(Su et al., 1995; Wu et al., 2004). Furthermore, recent fluores-
cence resonance energy transfer studies on more distantly
related proteins that contain CNB domains, such as the HCN
and CNG channels, have shown that CNB causes conforma-
tional rearrangement of the aC helices in their CNB domains, fa-
voring the opening of the channels (Puljung and Zagotta, 2013;
Taraska et al., 2009). Another atypical example comes from
recent structures of CNB homology domains in the ether-a-go-
go (EAG) channel, which does not bind cyclic nucleotides but
instead responds to changes in voltage when a short b strand
at the end of the aC helix occupies the binding pocket and
acts as an ‘‘intrinsic ligand’’ (Brelidze et al., 2012). Mutating res-
idues on the aC helix that occupy the binding pocket affects the
ability of EAG to respond to change in electrical potential, sug-
gesting that the positioning of the aC helix regulates EAG’s activ-
ity, even in the absence of cyclic nucleotide (Marques-Carvalho
et al., 2012). Taken together, these examples suggest that while
the aC helix in CNB domains has evolved in diverse ways, repo-
sitioning of the aChelix is a general mechanism used byCNBdo-
mains to regulate protein activity.
Consistent with these observations, the data presented here
suggest a role for the aC helix in CNB-B for PKG I activation
(Figure 4). In the absence of cGMP, the R-domain latches on
to the C-domain and keeps it inactive. Because the aC helix
interconnects the two domains, we hypothesize that the R-C
interaction immobilizes the aC helix leading to an ordered helical
state similar to what we observed in the apo structure. Uponª2014 Elsevier Ltd All rights reserved 121
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Tyr351, rearranging the aB and aC helices and causing disorder-
ing of the aC helix as seen in our CNB-B:cGMP complex struc-
ture. SAXS experiments on PKG Ib (53-686) showed that
cGMP binding to CNB-B is required for both elongation and acti-
vation (Wall et al., 2003). Thus, the conformational change in the
aB and aC helices on cGMP bindingmay contribute to release of
the C-domain in response to cGMP binding, resulting in kinase
activation. However, the exact activation mechanism awaits
more detailed structural studies on the global architecture of
PKG I.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Sequences encoding wild-type and mutant PKG Ib 219–369 were cloned into
pQTEV from a template containing full-length PKG Ib (GenBank ID
ABQ59040.1) (Bu¨ssow et al., 2005). The proteins were expressed by trans-
forming the construct into BL21(DE3) E. coli, growing the cells at 37C to
an optical density 600 nm (OD600nm) of 0.6, and inducing the cells with
0.5 mM isopropyl b-D-1-thiogalactopyranoside (IPTG). The cells were grown
for an additional 18 hr at 20C. Cells were resuspended in 50 mM potassium
phosphate, pH 7.0, 150 mM NaCl, 1 mM b-mercaptoethanol and lysed using
a cell disruptor (Constant Systems). His-tagged PKG Ib 219–369 was purified
with BioRad IMAC resin on a BioRad Profinia purification system. The protein
was eluted with cell suspension buffer containing 250 mM imidazole. To re-
move the His-tag, we incubated the sample with tobacco etch virus (TEV)
protease in a 50:1 M ratio at 4C overnight and loaded on to Bio-Rad
IMAC resin. The tagless samples were collected from flowthrough fractions.
A final buffer exchange into 25 mM Tris, pH 7.5, 150 mM NaCl, and 1 mM
TCEP was performed with a Hiload 16/60 Superdex 75 column (GE
Healthcare).
The sequence encoding wild-type PKGIb 92369 was similarly cloned into
pQTEV but was transformed into the Dcya TP2000 mutant strain of E. coli to
ensure no contamination by cAMP (Brickman et al., 1973). Purification was
performed using the same protocol as for PKG Ib 219–369.
Crystallization, Data Collection, Phasing, Model Building,
and Refinement
To obtain crystals of the CNB-B:cGMP complex, we preincubated the protein
sample with 5 mM equivalent cGMP and concentrated to 50 mg/ml using a
10 kDa cutoff Amicon Ultra (Millipore). Crystals were obtained using the
hanging drop method. Protein solution (2.5 ml) was mixed with 2 ml of reservoir
solution containing 1.6 M trisodium citrate, pH 6.5, and 0.5 ml of 1 M sodium
iodide. After 1 week incubation at 22C, drops produced bipyramidal crystals
belonging to a P41212 space group that diffracted to 1.65 A˚ resolution. Apo
crystals were obtained at a much higher concentration of 106 mg/ml at 4C
in a crystallizing solution containing 25% (w/v) polyethylene glycol 1500 and
0.1 M SPG buffer, pH 5.5. The apo crystal belongs to a P3121 space group
and diffracted to 2.0 A˚ resolution. All protein concentrations were measured
using a Bradford assay, and all crystals were cryoprotected with Paratone-N
before freezing.
Initial diffraction experiments on the CNB-B:cGMP crystals were performed
on a Rigaku FRE-SuperBright with a CuKa anode (1.54 A˚ wavelength). Data
were collected with 0.5 oscillation angles and 30 s exposures, and diffraction
was observed at 1.8 A˚ resolution. The data were processed using HKL-2000
(Minor et al., 2006). Thirteen initial iodide sites were located using Phenix
Autosol (Terwilliger et al., 2009), with a figure of merit equal to 0.53. An initial
model was obtained using Autobuild (Langer et al., 2008) and refined using
Phenix.Refine (Afonine et al., 2012) against a 1.65 A˚ data set collected at the
Advanced Photon Source. The final model was manually built using Coot
(Emsley and Cowtan, 2004).
Diffraction experiments on the apo crystals were performed at the
Advanced Photon Source. The structure was solved by MR using AutoMR
and a truncated version of the cGMP-bound structure of CNB-B as a search
model. The structure was built and refined as previously described.122 Structure 22, 116–124, January 7, 2014 ª2014 Elsevier Ltd All rigFP
The direct FP assay was performed following the procedure from Moll et al.
(2006). Measurements were performed in 150 mM NaCl, 20 mM MOPS plus
0.005% (w/v) CHAPS, pH 7.0, using the Fusion a-FP microtiter plate reader
at room temperature in a 384-well microtiterplate (Perkin Elmer, Optiplate,
black). The protein concentration was varied while the concentration of 8-
Fluo-cAMP/8-Fluo-cGMP (Biolog Life Science Institute) was fixed at 1–5 nM.
The FP signal was detected for 2 s at Ex 485 nm and Em 535 nm with a
photomultiplier voltage of 1,100. Data were analyzed with GraphPad Prism
5.03 (GraphPad Software) by plotting the polarization signal in mPol against
the logarithm of the protein concentration. The dissociation constant, KD,
values were calculated from sigmoidal dose-response curves.
In FP competition experiments, the protein concentration and the con-
centration of 8-Fluo-cGMP were fixed at a polarization signal of 50% of the
maximum value obtained from direct FP measurements. The protein was
incubated with 8-Fluo-cGMP and varying concentrations of unlabeled
cGMP or cAMP (Biolog Life Science Institute). FP signals were detected
as indicated earlier. Data were analyzed with GraphPad Prism 5.03 by
plotting the polarization signal in mPol against the logarithm of the cyclic
nucleotide concentration. The EC50 values were calculated from sigmoidal
dose-response curves.
SPR
Protein/nucleotide interactions were monitored as solution competition
experiments at 25C following the procedure from Moll et al. (2006) using a
Biacore T100 instrument (Biacore GE Healthcare). 8-AHT-cGMP (Biolog Life
Science Institute) was covalently coupled to a CM5 chip (research grade,
Biacore GE Healthcare) using standard amine coupling (Johnsson et al.,
1991). Binding experiments were performed in 20 mM MOPS, 100 mM NaCl
pH 7.0, plus 0.005% (v/v) surfactant P20 at 25C. Proteins were preincubated
with varying concentrations of unlabeled cAMP or cGMP, and the mixture
was subsequently injected over the nucleotide surfaces. Association was
monitored for 150–300 s, and the residual binding signal was collected at
the end of the association phase and plotted with GraphPad Prism 5.03
against the logarithm of the protein concentration. EC50 values were calcu-
lated from sigmoidal dose-response curves.
Microfluidic Mobility Shift Assay
HEK293T cells were grown to 80% confluency in complete medium and
transfected with FLAG-tagged wild-type and mutant PKG Ib constructs using
Lipofectamine 2000. After transfection, cells were lysed with 50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 with protease inhibitors.
Protein samples were purified by loading the lysate on to Anti-FLAG-M2
Agarose beads (Sigma-Aldrich), washing with 13 Tris-buffered saline
(TBS), and eluting with 13 TBS containing 5 mg/ml 33FLAG peptide
(Sigma-Aldrich).
Kinase activity was determined using a microfluidic mobility-shift assay on
a Caliper DeskTop Profiler (Caliper Life Sciences, PerkinElmer). Human
PKG Ib was incubated for 2 hr at 25C in a 384-well assay plate (Corning,
low volume, nonbinding surface) in 20 ml buffer (20 mM MOPS, pH 7.0,
150 mM NaCl, 0.1 mg/ml BSA, 1 mM dithiothreitol [DTT], 0.05% L-31,
10 mM fluorescein isothiocyanate-Kemptide, 990 mM Kemptide, 1 mM ATP,
10 mM MgCl2) and various concentrations of cGMP or cAMP (3 nM–5 mM),
respectively. Reaction mixtures without cyclic nucleotide were used as con-
trols. For electrophoretic separation of substrate and product, a ProfilerPro
LabChip (four-sipper mode; Caliper Life Sciences, PerkinElmer) was used un-
der the following conditions: downstream voltage 150 V, upstream voltage
1,800 V, with a screening pressure of 1.7 psi. Substrate conversion was
plotted against the logarithmic cyclic nucleotide concentration, and activation
constants (Ka) were calculated from sigmoidal dose-response curves using
GraphPad Prism 5.03.
NMR Analysis
The same construct used for crystallography was expressed with an N-termi-
nal poly-L-histidine tag, in E. coli strain BL21(DE3). The cells were grown at
37C in isotopically enriched minimal media supplemented with trace metals,
D-biotin, and thiamine-HCl. Expression was induced with 0.4 mM IPTG at anhts reserved
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C before
being harvested by centrifugation.
The harvested cells were lysed using a homogenizer, and cell debris was
subsequently removed by centrifugation (20,0003 g for 1 hr). For this process,
the cells were resuspended in 50 mM Tris buffer, pH 7.6, with 150 mM NaCl,
1 mM b-mercaptoethanol, and 0.2 mM AEBSF. An initial purification of the
PKG construct was then performed using Ni2+-Sepharose resin in a 5-ml
gravity column. After passing the cell lysate through the column, the column
was rinsed with lysis buffer, followed by 50 mM Tris buffer, pH 7.6, with
500 mM NaCl, 20 mM imidazole, and 1 mM b-mercaptoethanol. The protein
was then eluted from the column using 50 mM Tris buffer, pH 7.6, with
50 mM NaCl, 300 mM imidazole, and 1 mM b-mercaptoethanol.
The collected gravity column eluant was dialyzed in 50 mM Tris, 100 mM
NaCl, 1 mM b-mercaptoethanol, pH 7.6, and was cleaved with TEV protease
for 48 hr to remove the N-terminal poly-L-histidine tag from the PKG construct.
The tag and TEV protease were removed by passing the sample through a
Ni2+-Sepharose gravity column followed by dialysis buffer. The flowthrough
and rinse fractions were concentrated and loaded on to a HiLoad Superdex
75 column that was equilibrated with 50 mM Tris, 100 mM NaCl, 1 mM DTT,
0.2% (w/v) NaN3, pH 7.0. An apo sample for NMR analysis was prepared by
concentrating an aliquot of the purified protein solution to 300 mM and add-
ing 5% (v/v) D2O. A cGMP-bound sample was prepared similarly, with the
addition of 2 mM cGMP (Sigma-Aldrich) to the protein solution.
Two-dimensional 1H,15N HSQC and three-dimensional triple-resonance
NMR spectra were acquired for apo and cGMP-bound samples of PKG Ib
219–369. All NMR spectra were acquired at 306 K with a Bruker Avance
700-MHz NMR spectrometer equipped with a 5 mm TCI cryoprobe. The
spectra were processed with NMRPipe (Delaglio et al., 1995) and analyzed
using Sparky (Goddard and Kneller, 2006). Automated assignment and
secondary structure probability calculations were performed using the
PINE-NMR server, and assignments were confirmed by manual examination
of the spectra with Sparky (Bahrami et al., 2009).
Size Exclusion Chromatography
Size exclusion chromatography experiments to measure the molecular weight
of PKG Ib 92-369 were performed on a Superdex 75 10/300 GL column (GE
Healthcare) at 4C using 25 mM Tris, pH 7.5, 150 mM NaCl, and 1 mM DTT
as running buffer. Elution of PKGIb 92-269was compared against the following
standards: conalbumin, 75 kDa; ovalbumin, 44kDa; carbonic anhydrase,
29 kDa; ribonuclease A, 13.7 kDa; aprotinin, 6.5 kDa.
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Atomic coordinates and structure factors of the PKG Ib (219–369):cGMP com-
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(http://www.pdb.org) under accession numbers 4KU7 and 4KU8.
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